CN111918879B - 用于治疗表达LMA的癌症和自身免疫疾病的抗λ骨髓瘤抗原(LMA)结合蛋白 - Google Patents

用于治疗表达LMA的癌症和自身免疫疾病的抗λ骨髓瘤抗原(LMA)结合蛋白 Download PDF

Info

Publication number
CN111918879B
CN111918879B CN201980012636.9A CN201980012636A CN111918879B CN 111918879 B CN111918879 B CN 111918879B CN 201980012636 A CN201980012636 A CN 201980012636A CN 111918879 B CN111918879 B CN 111918879B
Authority
CN
China
Prior art keywords
seq
ser
set forth
leu
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980012636.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN111918879A (zh
Inventor
R·邓恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hamarojicos Co ltd
Original Assignee
Hamarojicos Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2018900534A external-priority patent/AU2018900534A0/en
Application filed by Hamarojicos Co ltd filed Critical Hamarojicos Co ltd
Publication of CN111918879A publication Critical patent/CN111918879A/zh
Application granted granted Critical
Publication of CN111918879B publication Critical patent/CN111918879B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201980012636.9A 2018-02-20 2019-02-20 用于治疗表达LMA的癌症和自身免疫疾病的抗λ骨髓瘤抗原(LMA)结合蛋白 Active CN111918879B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2018900534A AU2018900534A0 (en) 2018-02-20 Composition and method
AU2018900534 2018-02-20
PCT/AU2019/050137 WO2019161443A1 (en) 2018-02-20 2019-02-20 Anti-lambda myeloma antigen (lma) binding proteins to treat lma-expressing cancer and autoimmune disorders

Publications (2)

Publication Number Publication Date
CN111918879A CN111918879A (zh) 2020-11-10
CN111918879B true CN111918879B (zh) 2024-10-15

Family

ID=67686653

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980012636.9A Active CN111918879B (zh) 2018-02-20 2019-02-20 用于治疗表达LMA的癌症和自身免疫疾病的抗λ骨髓瘤抗原(LMA)结合蛋白

Country Status (10)

Country Link
US (2) US11447571B2 (https=)
EP (1) EP3755724A4 (https=)
JP (2) JP7490559B2 (https=)
KR (1) KR102824611B1 (https=)
CN (1) CN111918879B (https=)
AU (2) AU2019225446B2 (https=)
BR (1) BR112020017018A2 (https=)
CA (1) CA3091711A1 (https=)
SG (1) SG11202007925SA (https=)
WO (1) WO2019161443A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250326864A1 (en) * 2022-06-13 2025-10-23 Paradox Immunotherapeutics Inc. Monoclonal antibodies targeting conformation-specific epitopes of immunoglobulin light chains of the lambda subclass
WO2025236034A1 (en) * 2024-05-13 2025-11-20 HaemaLogiX Ltd Anti-lma binding proteins

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1946425A (zh) * 2004-02-27 2007-04-11 派克迈伯有限公司 B细胞疾病的靶
CN102802667A (zh) * 2009-04-07 2012-11-28 免疫系统治疗有限公司 用于治疗免疫失调的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100187181A1 (en) * 2009-01-29 2010-07-29 Sortwell Edwin T Method for Dispersing and Aggregating Components of Mineral Slurries
GB201203938D0 (en) * 2012-03-06 2012-04-18 Binding Site Group The Ltd Assay system

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1946425A (zh) * 2004-02-27 2007-04-11 派克迈伯有限公司 B细胞疾病的靶
CN102802667A (zh) * 2009-04-07 2012-11-28 免疫系统治疗有限公司 用于治疗免疫失调的方法

Also Published As

Publication number Publication date
CA3091711A1 (en) 2019-08-29
EP3755724A1 (en) 2020-12-30
JP2021514369A (ja) 2021-06-10
CN111918879A (zh) 2020-11-10
US20230174675A1 (en) 2023-06-08
JP2024100838A (ja) 2024-07-26
JP7798956B2 (ja) 2026-01-14
SG11202007925SA (en) 2020-09-29
US12435158B2 (en) 2025-10-07
US20210230309A1 (en) 2021-07-29
WO2019161443A1 (en) 2019-08-29
EP3755724A4 (en) 2022-03-23
BR112020017018A2 (pt) 2020-12-29
AU2021202092A1 (en) 2021-04-29
AU2019225446A1 (en) 2020-10-08
KR102824611B1 (ko) 2025-06-24
US11447571B2 (en) 2022-09-20
KR20210005553A (ko) 2021-01-14
JP7490559B2 (ja) 2024-05-27
AU2019225446B2 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
CN111094352B (zh) B7-h4抗体及其使用方法
CA2501984C (en) Erythropoietin receptor binding antibodies
CA2501653C (en) Human anti-ifn-.gamma. neutralizing antibodies as selective ifn-.gamma. pathway inhibitors
CN107531783B (zh) 靶向bmp6抗体的组合物和方法
KR102904286B1 (ko) 세포 부착 분자3에 결합하는 항체
US20040175379A1 (en) Erythropoietin receptor binding antibodies
CN115151570B (zh) 抗人cd19抗体
CN110799538B (zh) 抗cd3抗体及其制备和使用方法
KR20170065029A (ko) 증강된 면역 반응 및 암 요법을 위한 조성물 및 사용 방법
KR20220062500A (ko) 항-cd39 항체 조성물 및 방법
CN101027322A (zh) 促红细胞生成素受体结合抗体
WO2012172495A1 (en) Compositions and methods for antibodies targeting tem8
CN106795223B (zh) 针对Fcγ受体IIB及Fcε受体的抗体
KR20140059168A (ko) 시신경 척수염 치료용 조성물 및 치료 방법
CN110621699B (zh) Btla激动剂抗体及其用途
CN114685660A (zh) 抗cldn18.2抗体及其制备方法和应用
CN111918879B (zh) 用于治疗表达LMA的癌症和自身免疫疾病的抗λ骨髓瘤抗原(LMA)结合蛋白
CN101918549B (zh) 改良的人源化的抗-人α9-整联蛋白抗体
CN112175087B (zh) 一种抗CD4和TGFβ的双特异性抗体、其药物组合及其用途
KR20160072268A (ko) 항-efna4 항체-약물 접합체
CN117203241A (zh) 抗Siglec15抗体及其用途
KR20240004694A (ko) 항체
CN112851809A (zh) 一种抗终末糖基化蛋白受体的抗体及其应用
WO2023030311A1 (zh) 靶向Siglec15的抗原结合蛋白及其用途
HK40076013A (en) Anti-cldn18.2 antibody, and preparation method and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant